Immune Cell Bank Bets on Future CAR T Success
Nicoletta Lanese | Aug 16, 2019
The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.
CAR T Immunotherapy May Find New Use in Treating Cardiac Fibrosis
CAR T Immunotherapy May Find New Use in Treating Cardiac Fibrosis
Scientists show the approach can kill cells that cause hardening of heart tissue in mice.
Scientists show the approach can kill cells that cause hardening of heart tissue in mice.
Clinical Trials Bite Off Chunk of CAR T Therapy Market
Kerry Grens | Jul 30, 2019
About a quarter of lymphoma patients eligible for the cancer treatments are opting for experimental—and free—options instead.
T Cell Proliferation Linked to CAR T Responses
Ashley Yeager | Jul 15, 2019
Comparing the cells of cancer patients who did and did not respond to the immunotherapy could reveal biomarkers to predict who should receive it in the first place.
A Revised CAR T for Lymphoma Has Fewer Side Effects
Kerry Grens | Apr 23, 2019
An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.
The Next Frontier of CAR T-Cell Therapy: Solid Tumors
Kerry Grens | Apr 1, 2019
The technology has wowed the field by all but obliterating some patients’ blood cancers, but solid malignancies present new challenges.
Infographic: CAR-T Cells in Solid Versus Liquid Cancers
Kerry Grens | Apr 1, 2019
Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.
CAR T Cells Treat Lupus in Mice
Abby Olena | Mar 6, 2019
T cells modified to target disease-contributing B cells improved survival in two mouse models of the autoimmune disease.
Nature Retracts Paper on Delivery System for CAR T Immunotherapy
Diana Kwon | Feb 20, 2019
The manuscript had amassed more than 50 comments about problematic figures and data on PubPeer.
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Catherine Offord | Jan 3, 2019
The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.